227 related articles for article (PubMed ID: 35865316)
1. MicroRNA-21: A Critical Pathogenic Factor of Diabetic Nephropathy.
Liu S; Wu W; Liao J; Tang F; Gao G; Peng J; Fu X; Zhan Y; Chen Z; Xu W; Zhao S
Front Endocrinol (Lausanne); 2022; 13():895010. PubMed ID: 35865316
[TBL] [Abstract][Full Text] [Related]
2. Roles of microRNA-192 in diabetic nephropathy: the clinical applications and mechanisms of action.
Wan X; Liao J; Lai H; Zhang S; Cui J; Chen C
Front Endocrinol (Lausanne); 2023; 14():1179161. PubMed ID: 37396169
[TBL] [Abstract][Full Text] [Related]
3. Ski-related novel protein suppresses the development of diabetic nephropathy by modulating transforming growth factor-β signaling and microRNA-21 expression.
Wang Y; Liu L; Peng W; Liu H; Liang L; Zhang X; Mao Y; Zhou X; Shi M; Xiao Y; Zhang F; Zhang Y; Liu L; Yan R; Guo B
J Cell Physiol; 2019 Aug; 234(10):17925-17936. PubMed ID: 30847937
[TBL] [Abstract][Full Text] [Related]
4. miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7.
McClelland AD; Herman-Edelstein M; Komers R; Jha JC; Winbanks CE; Hagiwara S; Gregorevic P; Kantharidis P; Cooper ME
Clin Sci (Lond); 2015 Dec; 129(12):1237-49. PubMed ID: 26415649
[TBL] [Abstract][Full Text] [Related]
5. miR-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy.
Wang JY; Gao YB; Zhang N; Zou DW; Wang P; Zhu ZY; Li JY; Zhou SN; Wang SC; Wang YY; Yang JK
Mol Cell Endocrinol; 2014 Jul; 392(1-2):163-72. PubMed ID: 24887517
[TBL] [Abstract][Full Text] [Related]
6. BMP-7 inhibits renal fibrosis in diabetic nephropathy via miR-21 downregulation.
Liu L; Wang Y; Yan R; Liang L; Zhou X; Liu H; Zhang X; Mao Y; Peng W; Xiao Y; Zhang F; Liu L; Shi M; Guo B
Life Sci; 2019 Dec; 238():116957. PubMed ID: 31655195
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-β/Smad signalling in diabetic nephropathy.
Lan HY
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):731-8. PubMed ID: 22211842
[TBL] [Abstract][Full Text] [Related]
8. [The Role of TGF-β1/SMAD in Diabetic Nephropathy: Mechanisms and Research Development].
Wang Y; Guo J; Shao B; Chen H; Lan H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1065-1073. PubMed ID: 38162063
[TBL] [Abstract][Full Text] [Related]
9. Identification of biomarkers and prediction of upstream miRNAs in diabetic nephropathy.
Yin D; Guo Z; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1144331. PubMed ID: 36896170
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-β and Smads.
Lan HY; Chung ACK
Contrib Nephrol; 2011; 170():75-82. PubMed ID: 21659760
[TBL] [Abstract][Full Text] [Related]
11. TGF-Beta as a Master Regulator of Diabetic Nephropathy.
Wang L; Wang HL; Liu TT; Lan HY
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360646
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-140-5p ameliorates the high glucose-induced apoptosis and inflammation through suppressing TLR4/NF-κB signaling pathway in human renal tubular epithelial cells.
Su J; Ren J; Chen H; Liu B
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32073611
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of miR-17 suppresses TGF-β1-mediated renal fibrosis through targeting Smad7.
Fu H; Chu D; Geng X
Mol Cell Biochem; 2021 Aug; 476(8):3051-3064. PubMed ID: 33797702
[TBL] [Abstract][Full Text] [Related]
14. MiR-130b increases fibrosis of HMC cells by regulating the TGF-β1 pathway in diabetic nephropathy.
Ma Y; Shi J; Wang F; Li S; Wang J; Zhu C; Li L; Lu H; Li C; Yan J; Zhang X; Jiang H
J Cell Biochem; 2019 Mar; 120(3):4044-4056. PubMed ID: 30260005
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-27a promotes renal tubulointerstitial fibrosis via suppressing PPARγ pathway in diabetic nephropathy.
Hou X; Tian J; Geng J; Li X; Tang X; Zhang J; Bai X
Oncotarget; 2016 Jul; 7(30):47760-47776. PubMed ID: 27351287
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor β1 (TGF-β1) enhances expression of profibrotic genes through a novel signaling cascade and microRNAs in renal mesangial cells.
Castro NE; Kato M; Park JT; Natarajan R
J Biol Chem; 2014 Oct; 289(42):29001-13. PubMed ID: 25204661
[TBL] [Abstract][Full Text] [Related]
17. Silencing of long noncoding RNA XIST protects against renal interstitial fibrosis in diabetic nephropathy via microRNA-93-5p-mediated inhibition of CDKN1A.
Yang J; Shen Y; Yang X; Long Y; Chen S; Lin X; Dong R; Yuan J
Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1350-F1358. PubMed ID: 31545928
[TBL] [Abstract][Full Text] [Related]
18. High glucose down-regulates microRNA-181a-5p to increase pro-fibrotic gene expression by targeting early growth response factor 1 in HK-2 cells.
Xu P; Guan MP; Bi JG; Wang D; Zheng ZJ; Xue YM
Cell Signal; 2017 Feb; 31():96-104. PubMed ID: 28077323
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-β-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy.
Deshpande SD; Putta S; Wang M; Lai JY; Bitzer M; Nelson RG; Lanting LL; Kato M; Natarajan R
Diabetes; 2013 Sep; 62(9):3151-62. PubMed ID: 23649518
[TBL] [Abstract][Full Text] [Related]
20. Adipose mesenchymal stem cell-derived extracellular vesicles containing microRNA-26a-5p target TLR4 and protect against diabetic nephropathy.
Duan Y; Luo Q; Wang Y; Ma Y; Chen F; Zhu X; Shi J
J Biol Chem; 2020 Sep; 295(37):12868-12884. PubMed ID: 32580945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
